# Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection

> **NCT02202980** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 273 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** LDV/SOF
- **DRUG:** RBV
- **DRUG:** SOF/VEL
- **DRUG:** VOX

## Key facts

- **NCT ID:** NCT02202980
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08-04
- **Primary completion:** 2016-03-16
- **Final completion:** 2016-05-09
- **Target enrollment:** 273 (ACTUAL)
- **Last updated:** 2018-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02202980

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02202980, "Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02202980. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*